Federal Official Gazette
No updates.
ANS news
Public Hearing No. 66
Collection of input on the preliminary recommendation against incorporation for the following technologies: UAT 188 – Bimekizumab for the treatment of moderate to severe active hidradenitis suppurativa in adults who have failed, shown intolerance to, or have a contraindication to systemic antibiotic therapy; and UAT 198 – Capivasertib for the treatment of locally advanced or metastatic breast cancer, HR+ and HER2-, with one or more alterations in PIK3CA/AKT1/PTEN. Date: May 22, 2026, from 9:30 a.m. to 12:30 p.m.
637th Meeting of the Board of Directors
The meeting takes place this Friday (May 15), with live broadcast starting at 10 a.m. Agenda attached.
Open public consultations
- CP 172. Its purpose is to receive input on the proposed updates to the List of Health Procedures and Events (Rol). Deadline: May 13, 2026 to June 2, 2026.
Scheduled public hearings
- New: AP 66. Collection of input on the preliminary recommendation against incorporation for the following technologies: UAT 188 – Bimekizumab for the treatment of moderate to severe active hidradenitis suppurativa in adults who have failed, shown intolerance to, or have a contraindication to systemic antibiotic therapy; and UAT 198 – Capivasertib for the treatment of locally advanced or metastatic breast cancer, HR+ and HER2-, with one or more alterations in PIK3CA/AKT1/PTEN. Date: May 22, 2026, from 9:30 a.m. to 12:30 p.m.
Open public calls for input
There is no open public call for input.
Open public calls
No updates.
Other news
– No updates.
Sources: Federal Official Gazette (DOU) and the ANS website. Press items link to the original article. This brief is for information only and does not constitute legal advice.